Pharmaceutical Research banner
  • "Adverse Drug Reaction (ADR) Reporting and Pharmacovigilance of Biological Medicines: A Survey among Health Care Professionals in South India." by Ann Maria Sunny

    Ann Maria SunnyThe essence of the study was to assess the knowledge, awareness and attitude of healthcare professionals in India towards the ADR reporting of biologicals. The study also tried to figure out the factors affecting and challenges involved in the reporting of ADR. The study entailed ADR in general and ADR of biologicals. There are no studies that address the knowledge of HCPs on the pharmacovigilance of biological medicines except the one conducted in Ireland. It is worth investigating about the knowledge, attitude and perception of HCPs about the pharmacovigilance of biologicals and biosimilars as the legislations and regulations regarding the same came into effect in the recent years.

     

     


    Read more/less

     

     Objectives:

    • To evaluate the knowledge and practice of ADR reporting in India.

    • To assess the behavior, attitude and awareness related to PV of biological medicines among HCPs in India.

    • To identify the factors and challenges in reporting ADR of biological medicines.

    • To suggest methods to expand and increase the ADR reporting of biosimilars.

    Methodology:

    A cross-sectional observational study was carried out using a pre-designed questionnaire consisting of 24 questions. Both qualitative and quantitative approaches were chosen to investigate among 100 HCPs (doctors, nurses and pharmacists) selected by non-probability convenience sampling method in Kerala, India. The statistical analysis of the quantitative data was performed using SPSS statistics software. Association between dependent and independent variables was found by using Pearson’s Chi-Square Test were p < 0.05 was considered to be statistically significant. The responses to the qualitative questions were interpreted using coding method and thematic analysis using Pareto chart was used to draw out conclusion.
     
    Findings:

    The study found that the knowledge and attitude of HCPs towards ADR reporting is improving and the practice of reporting ADR is still deficient. A good proportion of the HCPs are aware about the importance of pharmacovigilance of biological medicine and biosimilars. They also know the significance of traceability of these products. However, 73% of the participants stated that they never conducted any additional monitoring for new biological medicines. Around 50% of the participants identified lack of knowledge and busy schedule as the major challenge in reporting ADR of biologicals.73 % of the participants pointed out the need for more training sessions on pharmacovigilance. It is clear from the responses that clinical pharmacists and doctors seems to have better knowledge on pharmacovigilance when compared to nurses and other pharmacists.

    Analysis:

    The data collected from the questionnaire were analyzed both quantitatively and qualitatively. All the quantitative analysis was performed using SPSS statistics software. The analysis included analyzing the frequency and mean of responses and also Pearson’s Chi-Square test. The open-ended questions are descriptively explained and analyzed using Pareto charts. The questionnaire were subdivided into following topics and analysed accordingly: Knowledge on PV and ADR, Reporting of ADR, PV of biologicals, Traceability of biological products ,Knowledge on PV and ADR monitoring of biologicals , Familiarity with biosimilars, Training programs, Reporting ADR of biologicals.

    Conclusions:

    The knowledge and attitude towards ADR reporting of biological medicines and biosimilars are gradually improving whereas the practice of reporting ADR is still deficient. A substantial proportion of doctors, nurses, and pharmacists have been found to lack trust in their own awareness of ADR reporting, demonstrating the value of ongoing pharmacovigilance education and training for HCP. The challenges identified in this study on reporting of ADR in general and that of ADR of biologicals are in agreement with the results found by different authors in different parts of the world. The majority of the respondents suggested that more frequent training sessions are required to improve knowledge on PV and ADR reporting. Among the professionals working in the hospital, the doctors and clinical pharmacists seems to have better knowledge about the PV and ADR reporting of biologicals. From the comparison of responses of HCPs, it is clear that the HCPs working in hospital set up has more exposure towards biologicals when compared to community pharmacists.

  • "An Analysis on the Assessment and Reporting of Adverse Drug Reactions in Tertiary Hospitals in Lagos State, South-West Nigeria." by Zainab Abolanle Atobatele

    Zainab Atobatele

    Due to the repeated occurrence of serious, unexpected ADR over the years, lots of professionals and public attention has been drawn to ADRs, and this has led to more focused attention on drug safety surveillance system. ADR incidence is associated with high rate of morbidity and mortality and this incidence cuts across all age groups with a large number of hospitalization, and huge financial burden on Nigeria healthcare system and society. Unfortunately, the assessment, monitoring, and reporting system of ADR in Nigeria healthcare system still have lots of room for improvements, especially with the involvement of tertiary hospitals in Nigeria.

     

     

    Read more/less

     

     Objectives:

    This research aims to identify bottlenecks and loopholes that hinder effective ADR practice in tertiary hospitals in Lagos state Nigeria. The research involved major stakeholder of pharmacovigilance activities which includes; HCPs (Doctors, Nurses, and pharmacists) and patients.

    1) To assess the knowledge, attitude, and practice of HCPs towards Pharmacovigilance and ADR in Lagos state tertiary hospitals.

    2) Determine HCPs' perception towards direct patient reporting of ADR.

    3) To elicit patients' experience regarding ADR reporting and evaluate its impacts on pharmacovigilance structure.

    4) To make sustainable recommendations which invariably will contribute to the overall pharmacovigilance system in place in the hospitals.

    Methodology:

    This research was modelled on a mixed-method approach that was underlined by a deductive approach and positivist philosophy. The primary data was collected using an online survey and phone interview. The survey was targeted at 450 participants, and a total of 405 respondents were obtained in return in which 270 were patients, and 135 were HCPs (doctors, nurses, and pharmacists) recording a response rate of 90%. For the interview, 12 people were scheduled to be interviewed but 6 responses were obtained which includes 2 doctors, 2 nurses, and 2 pharmacists recording a response rate of (50%).

    Findings:

    From the analysis conducted a significant number of HCPs participants have basic understanding of ADR but have no knowledge of causality assessment and they established that they are not sufficiently trained on how to assess and report ADR. Several bottlenecks such as lack of knowledge/awareness, lack of feedback from NPC, unavailability of ADR reporting forms, insufficient staffs, and excessive workload were established as most challenging issues. However, a highly significant number 92% are willing to update their knowledge on ADR practice and opted to make it a mandatory obligation to help resolve underreporting issues faced by the country. A significant number of Patients participants established they are not familiar with ADR and the importance of reporting, while HCPs acknowledged they are not aware that patients can report ADR directly neither do they think it’s a good idea because they are of the perception that patients can’t generate valid/quality ADR reports.

    Analysis:

    Although the regulatory agency in Nigeria (NAFDAC) has set in place the ideal models needed for reporting, however, their performance towards awareness and publicity of ADR was rated poorly and this in turn is a huge barrier in promoting drug safety practice and pharmacovigilance system in Nigeria. However, from reviewed literature and findings obtained from the study, it can be deduced that global underreporting issues are significantly associated with lack of knowledge and adequate resources dedicated to identify, assess, monitor, and report potential ADRs effectively. The reporting and assessing medium in Nigeria tertiary hospitals are inadequately efficient and somehow being underutilized by Nigerians including its HCPs and healthcare providers due to lack of dedicated resources to the process, and persistent focus on knowledge acquisition instead of its implementation and feasibility. The resulting effect of this act is the burden of ADR faced by the country and inability to achieve required ADR reported cases despite the high mortality and morbidity rate associated with ADR cases in the country.

    Conclusions:

    Nigeria is earmarked as a fast developing country and a leading nation in the future, therefore the country has to be established in all aspects especially the healthcare system starting with its HCPs and regulatory agency. Patients should be educated, encouraged, and actively involved on ADR reporting because they have the potential to add value to generated reports by providing more detailed reports which can help detect likely causality and impact on patients’ lives. Creating more awareness, organising frequent training, workshop, and seminars to update the knowledge of HCP, dedicating adequate resources, incorporating ADR module into the curriculum of HCPs during their undergraduate and orientation program when newly employed, establishing an active pharmacovigilance centres in tertiary hospitals to help monitor and guide ADR practice, educating and encouraging patients on ADR reporting and its importance, are sustainable recommendations that will improve ADR practice and contribute invariably to pharmacovigilance system in Nigeria.

© 2018 Innopharma. All rights reserved.

PrivacyTerms of UseHome